2024-11-12 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report 

**1. Performance Comparison and Alpha/Beta Analysis**

Merck & Co Inc (MRK) is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products. 

**Performance Comparison:**
* MRK's cumulative return is **59.64%**, while the S&P 500 (VOO) has returned **142.82%**.
* This results in a **-83.18%** difference, indicating that MRK has significantly underperformed the market.
* The **Relative Divergence** of **3.31%** suggests that MRK is currently outperforming the S&P 500 compared to its historical performance, but the difference is still considerable.

**Alpha/Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Market Cap (B) |
|------------|------|------|-------|------|---------------|
| 2015-2017  | -1.6% | 18.1% | -31.8% | 0.9 | 135.82 |
| 2016-2018  | 45.6% | 17.0% | 20.9% | 0.7 | 184.44 |
| 2017-2019  | 51.2% | 17.0% | 8.1% | 0.7 | 219.53 |
| 2018-2020  | 45.5% | 27.2% | 6.4% | 0.7 | 197.45 |
| 2019-2021  | 6.3% | 27.2% | -83.6% | 0.6 | 193.87 |
| 2020-2022  | 26.3% | 27.2% | 8.6% | 0.5 | 280.66 |
| 2021-2023  | 41.1% | 19.8% | 12.3% | 0.3 | 275.78 |
| 2022-2024  | 33.9% | 23.2% | 8.7% | 0.3 | 255.92 |

**Analysis:**
* MRK's alpha is generally positive, indicating that it has outperformed the market in most periods. However, the recent alpha is lower, reflecting the company's underperformance.
* Beta values indicate that MRK is less volatile than the market (beta < 1) but has been getting closer to the market's volatility over the past few years.

**2. Recent Price Movement**

* **Closing Price:** 102.92 
* **Last Market Price:** 101.07
* **5-day Moving Average:** 101.67
* **20-day Moving Average:** 105.23
* **60-day Moving Average:** 111.61

**Analysis:**
* MRK's price has been trending downwards recently, as the current price is below all three moving averages.
* The 5-day and 20-day moving averages are relatively close, indicating a potential short-term rebound.

**3. Technical Indicators Analysis**

* **RSI:** 34.59 (Below 50)
* **PPO:** -0.05 (Negative)
* **Delta_Previous_Relative_Divergence:** -16.31 (-):  Short-term downtrend. 
* **Expected Return:** 0.0% (Long-term expected return relative to S&P 500). 

**Analysis:**
* The RSI suggests that MRK is currently oversold, indicating potential for a bounce back.
* However, the negative PPO and negative Delta_Previous_Relative_Divergence highlight the recent downward trend and short-term downward pressure. 

**4. Recent Earnings & Outlook**

| Date       | EPS | Revenue     |
|------------|-----|-------------|
| 2024-11-06 | 1.25 | $16.66 B$ |
| 2024-08-05 | 2.15 | $16.11 B$ |
| 2024-05-03 | 1.88 | $15.78 B$ |
| 2023-11-03 | 1.87 | $15.96 B$ |
| 2024-11-06 | 1.87 | $15.96 B$ |

**Analysis:**
* MRK has been consistently exceeding revenue expectations, but recent EPS has fallen short of analysts' estimates. 
* The most recent earnings report is yet to be released, and it will be crucial to see how MRK performs compared to analyst expectations.

**5. Financial Information**

**1) Revenue and Profitability**

| Quarter       | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2024-09-30 | $16.66B$ | 75.51%       |
| 2024-06-30 | $16.11B$ | 76.76%       |
| 2024-03-31 | $15.78B$ | 77.56%       |
| 2023-12-31 | $14.63B$ | 73.26%       |
| 2023-09-30 | $15.96B$ | 73.29%       |

**2) Capital and Profitability**

| Quarter       | Equity    | ROE |
|------------|-----------|-----|
| 2024-09-30 | $44.50B$ | 7.09% |
| 2024-06-30 | $43.58B$ | 12.52% |
| 2024-03-31 | $40.36B$ | 11.80% |
| 2023-12-31 | $37.58B$ | -3.26% |
| 2023-09-30 | $41.25B$ | 11.50% |

**Analysis:**

* MRK has consistently demonstrated strong profitability, with high profit margins and generally good return on equity.
* The recent quarter's ROE dip could be a concern, but it is important to consider the overall trend and any potential one-time factors.

**6. News and Recent Issues**

* **Recent Earnings News:**  
    * Recent earnings calls and analyst reports should be reviewed for information about MRK's performance and future outlook.
* **Market Outlook:** 
    * Review recent market analyses on MRK, focusing on factors impacting the pharmaceutical industry and the company's competitive landscape.
* **Analyst Opinions:**
    * Check analyst ratings and price targets for MRK to understand the general consensus on the stock.

**7. Overall Analysis**

MRK is a large, established pharmaceutical company with a strong track record of profitability. However, its recent underperformance relative to the market and the decline in EPS growth are concerning. While the company has shown some positive signs in recent quarters, investors should carefully consider the current market environment and the company's future prospects before making any investment decisions. Technical indicators suggest potential for a short-term rebound, but a long-term perspective should be maintained, considering the current market landscape and the company's growth strategy.

**8. Report Summary**

This report analyzed MRK's stock performance, financial information, and recent news. Key findings include:

* MRK has significantly underperformed the S&P 500 in the past year.
* While MRK has generally outperformed the market historically, recent performance has been weaker.
* Technical indicators suggest potential for a short-term rebound, but the long-term outlook remains uncertain.
* MRK's financial performance remains strong, but investors should monitor the company's revenue and earnings growth.

**Disclaimer:** This report is for informational purposes only and should not be considered as financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial professional.